Chronic Paediatric Conditions — MCQs
On this page
A 6-year-old boy with a history of three afebrile generalized tonic-clonic seizures over the past 6 months undergoes an EEG. The EEG shows 3 Hz spike-and-wave discharges on a normal background. His parents report he sometimes has brief episodes of staring with eyelid fluttering that last 5-10 seconds. Neurological examination is normal. What is the most likely diagnosis?
A 9-year-old girl with type 1 diabetes for 4 years attends clinic with her parents. She uses a basal-bolus insulin regimen with insulin detemir twice daily and insulin aspart with meals. Her mother reports that she has been experiencing episodes of unusual behaviour in the early morning, including confusion and aggression, which resolve after eating breakfast. Her evening blood glucose readings are typically 8-10 mmol/L. What is the most appropriate management strategy?
A 16-year-old girl with juvenile myoclonic epilepsy controlled on levetiracetam presents with deteriorating school performance and social withdrawal over 6 months. Her parents report increased irritability and episodes where she cries without obvious reason. She has been seizure-free for 2 years. On direct questioning, she admits to feeling low most days but denies suicidal ideation. What is the most appropriate management approach considering her epilepsy and mental health?
An 11-year-old boy with type 1 diabetes presents with his third episode of severe hypoglycaemia requiring third-party assistance in 6 months. His parents report he no longer experiences warning symptoms before hypoglycaemic episodes. His average blood glucose from his meter is 7.8 mmol/L with significant variability. HbA1c is 54 mmol/mol. What is the most appropriate strategy to restore hypoglycaemia awareness?
A 6-year-old girl with epilepsy has been taking sodium valproate for 18 months with good seizure control. Her mother reports that she has recently noticed increased bruising and two episodes of epistaxis. Blood tests show: Haemoglobin 118 g/L, White cell count 6.8 × 10⁹/L, Platelets 185 × 10⁹/L, PT 13 seconds (normal range 11-14), APTT 38 seconds (normal range 26-34). What is the most likely explanation for these findings?
A 13-year-old boy with type 1 diabetes for 7 years presents for his annual complication screening. Urinalysis shows albumin:creatinine ratio (ACR) of 3.5 mg/mmol on an early morning sample. Two further early morning samples over the next 3 months show ACR values of 3.8 mg/mmol and 4.1 mg/mmol. His blood pressure is 118/72 mmHg (95th percentile for age). HbA1c is 71 mmol/mol. eGFR is normal. What is the most appropriate initial management for his kidney disease?
A 4-year-old boy presents to the emergency department with a focal seizure involving right-sided facial twitching that has been ongoing for 35 minutes. He remains conscious but unable to speak. There is no fever. He has no previous history of seizures. What is the most appropriate immediate management?
A 10-year-old girl with type 1 diabetes for 4 years presents with a 6-week history of intermittent abdominal pain, loose stools, and failure to gain weight. She has lost 2 kg. Her HbA1c has improved from 65 to 52 mmol/mol without changes to her insulin regimen. On examination, she appears pale and has angular stomatitis. What is the most likely diagnosis?
A 15-year-old girl with juvenile myoclonic epilepsy has been well-controlled on sodium valproate for 2 years. She now presents requesting advice about contraception as she is sexually active. Liver function tests and full blood count are normal. She has no plans for pregnancy. What is the most appropriate management regarding her anti-epileptic medication?
A 12-year-old boy with type 1 diabetes for 5 years attends for routine screening. He is asymptomatic but fundoscopy reveals multiple microaneurysms and scattered dot-and-blot haemorrhages in both eyes, with no macular involvement or cotton wool spots. His HbA1c is 68 mmol/mol. What grade of diabetic retinopathy does this represent and what is the most appropriate management?
Chronic Paediatric Conditions UK Medical PG Practice Questions and MCQs
Question 51: A 6-year-old boy with a history of three afebrile generalized tonic-clonic seizures over the past 6 months undergoes an EEG. The EEG shows 3 Hz spike-and-wave discharges on a normal background. His parents report he sometimes has brief episodes of staring with eyelid fluttering that last 5-10 seconds. Neurological examination is normal. What is the most likely diagnosis?
- A. Juvenile myoclonic epilepsy
- B. Childhood absence epilepsy (Correct Answer)
- C. Benign rolandic epilepsy
- D. Lennox-Gastaut syndrome
- E. Panayiotopoulos syndrome
Explanation: ***Childhood absence epilepsy*** - The classic EEG finding of **3 Hz spike-and-wave discharges** on a normal background is pathognomonic for this condition. - Clinical presentation involving **brief staring spells** with **eyelid fluttering** lasting 5-10 seconds and age-appropriate onset (6 years) aligns with typical absence seizures, which can occasionally be associated with **generalized tonic-clonic seizures**. *Juvenile myoclonic epilepsy* - This typically presents in **adolescence** (ages 12-18) rather than early childhood and is characterized by early morning **myoclonic jerks**. - The EEG for this condition would more likely show **4-6 Hz polyspike-and-wave** discharges rather than the classic 3 Hz pattern. *Benign rolandic epilepsy* - Also known as benign epilepsy with centrotemporal spikes (BECTS), it usually presents with **focal seizures** involving the face, oropharynx, or drooling, often during sleep. - The EEG diagnostic hallmark is **centrotemporal spikes** rather than generalized spike-and-wave discharges. *Lennox-Gastaut syndrome* - This is severe childhood epilepsy characterized by a triad of multiple seizure types, **intellectual disability**, and an abnormal EEG pattern. - Expect an EEG showing **slow spike-and-wave discharges** (usually <2.5 Hz) and a background that is typically abnormal/slowed. *Panayiotopoulos syndrome* - A benign focal epilepsy presenting with **autonomic symptoms** like vomiting, pallor, or sweating, often during sleep. - The EEG shows focal **occipital spikes** or multifocal spikes, which contrasts with the generalized discharges seen in this patient.
Question 52: A 9-year-old girl with type 1 diabetes for 4 years attends clinic with her parents. She uses a basal-bolus insulin regimen with insulin detemir twice daily and insulin aspart with meals. Her mother reports that she has been experiencing episodes of unusual behaviour in the early morning, including confusion and aggression, which resolve after eating breakfast. Her evening blood glucose readings are typically 8-10 mmol/L. What is the most appropriate management strategy?
- A. Increase the evening dose of insulin detemir
- B. Switch to insulin glargine once daily at bedtime
- C. Reduce the evening dose of insulin detemir (Correct Answer)
- D. Add a bedtime snack containing complex carbohydrates
- E. Increase the dinner-time dose of insulin aspart
Explanation: ***Reduce the evening dose of insulin detemir***- The child's early morning confusion and aggression resolving after breakfast are classic symptoms of **nocturnal hypoglycaemia**, indicating that the basal insulin dose is too high.- Reducing the evening dose of **insulin detemir**, which provides overnight basal coverage, directly addresses the underlying cause of the low blood glucose episodes.*Increase the evening dose of insulin detemir*- This strategy would **exacerbate nocturnal hypoglycaemia**, leading to more frequent or severe episodes of low blood sugar during the night.- Administering more **basal insulin** when a patient is already experiencing hypoglycaemia is an inappropriate and potentially dangerous intervention.*Switch to insulin glargine once daily at bedtime*- While insulin glargine is a long-acting insulin, simply switching formulations without adjusting the **total basal insulin dose** will not necessarily resolve the hypoglycaemic episodes.- The primary issue is the **excessive basal effect** overnight, not the specific type of long-acting insulin used.*Add a bedtime snack containing complex carbohydrates*- A bedtime snack might temporarily prevent early nocturnal hypoglycaemia, but it fails to address the fundamental problem of **over-insulinization**.- This approach can lead to **unwanted weight gain** and might only shift the timing of hypoglycaemia or cause rebound hyperglycaemia.*Increase the dinner-time dose of insulin aspart*- Increasing the dose of **insulin aspart**, a rapid-acting insulin, would primarily lower post-dinner blood glucose levels, potentially leading to **hypoglycaemia earlier in the night**.- The early morning symptoms point to an issue with the **basal insulin** effect, not the prandial insulin for dinner.
Question 53: A 16-year-old girl with juvenile myoclonic epilepsy controlled on levetiracetam presents with deteriorating school performance and social withdrawal over 6 months. Her parents report increased irritability and episodes where she cries without obvious reason. She has been seizure-free for 2 years. On direct questioning, she admits to feeling low most days but denies suicidal ideation. What is the most appropriate management approach considering her epilepsy and mental health?
- A. Recognize depression as a potential adverse effect of levetiracetam; consider switching to lamotrigine and commence SSRI therapy with monitoring (Correct Answer)
- B. Diagnose adjustment disorder related to chronic illness; refer for cognitive behavioural therapy without changing anti-epileptic medication
- C. Interpret symptoms as typical adolescent behaviour; provide reassurance and routine follow-up in 6 months
- D. Add sodium valproate for mood stabilization while continuing levetiracetam
- E. Stop levetiracetam immediately and observe for symptom resolution before starting alternative anti-epileptic drug
Explanation: ***Recognize depression as a potential adverse effect of levetiracetam; consider switching to lamotrigine and commence SSRI therapy with monitoring***- **Levetiracetam** is well-known for causing **behavioral adverse effects** such as irritability and depression in up to 15% of patients, which matches this patient's clinical presentation.- **Lamotrigine** is an effective alternative for **Juvenile Myoclonic Epilepsy (JME)** and possesses **mood-stabilizing properties**, while **SSRIs** are safe and do not significantly lower the **seizure threshold**.*Diagnose adjustment disorder related to chronic illness; refer for cognitive behavioural therapy without changing anti-epileptic medication*- While **CBT** is a valuable supportive therapy, failing to address the **iatrogenic cause** (levetiracetam) ignores the primary trigger for the mood change.- **Adjustment disorder** is less likely given the 6-month duration and the strong temporal association with potential drug-induced side effects.*Interpret symptoms as typical adolescent behaviour; provide reassurance and routine follow-up in 6 months*- **Functional impairment**, such as deteriorating school performance and social withdrawal, indicates a pathological state rather than normal adolescent development.- A 6-month delay in follow-up is dangerous as it ignores the risk of **clinical depression** progression and potential **suicidal ideation** development.*Add sodium valproate for mood stabilization while continuing levetiracetam*- **Sodium valproate** is strictly contraindicated for females of **childbearing potential** unless no other alternative exists due to its high risk of **teratogenicity**.- Continuing levetiracetam while adding a second drug fails to remove the most likely cause of the **psychiatric symptoms** and increases the drug burden.*Stop levetiracetam immediately and observe for symptom resolution before starting alternative anti-epileptic drug*- **Abrupt withdrawal** of an anti-epileptic drug carries a high risk of **rebound seizures** or **status epilepticus**.- Management of a seizure-free patient requires a careful **cross-tapering** strategy where the new drug is introduced before the old one is completely withdrawn.
Question 54: An 11-year-old boy with type 1 diabetes presents with his third episode of severe hypoglycaemia requiring third-party assistance in 6 months. His parents report he no longer experiences warning symptoms before hypoglycaemic episodes. His average blood glucose from his meter is 7.8 mmol/L with significant variability. HbA1c is 54 mmol/mol. What is the most appropriate strategy to restore hypoglycaemia awareness?
- A. Meticulous avoidance of hypoglycaemia by accepting higher glucose targets (>7 mmol/L) for 3-6 months (Correct Answer)
- B. Increase frequency of blood glucose monitoring to 10-12 times daily
- C. Switch from multiple daily injections to continuous subcutaneous insulin infusion (insulin pump)
- D. Reduce total daily insulin dose by 20% immediately
- E. Prescribe continuous glucose monitoring with predictive low glucose alerts
Explanation: ***Meticulous avoidance of hypoglycaemia by accepting higher glucose targets (>7 mmol/L) for 3-6 months*** - The most effective strategy to restore **hypoglycemia awareness** is a sustained period of meticulous avoidance of all hypoglycemic episodes, allowing the body's **counter-regulatory hormone** responses to reset. - Accepting temporarily higher **glucose targets** (e.g., >7 mmol/L) creates a buffer zone, preventing the brain from repeatedly adapting to low glucose and thus re-sensitizing the autonomic warning symptoms. *Increase frequency of blood glucose monitoring to 10-12 times daily* - While increased monitoring helps in detecting **hypoglycaemia** more promptly, it does not directly restore the blunted physiological **autonomic warning symptoms** which are crucial for awareness. - It serves as a detection tool but does not address the underlying desensitization of the body's response to low glucose. *Switch from multiple daily injections to continuous subcutaneous insulin infusion (insulin pump)* - An **insulin pump** can offer more precise insulin delivery and potentially reduce glucose variability, which may help reduce the frequency of hypoglycaemia. - However, the mode of insulin delivery itself does not directly restore **hypoglycaemia awareness**; rather, the critical factor is a sustained period of avoiding low blood glucose levels. *Reduce total daily insulin dose by 20% immediately* - An immediate and arbitrary reduction of the **total daily insulin dose** by 20% can lead to uncontrolled **hyperglycaemia** and is not a nuanced approach to restore awareness. - The goal is careful titration and adjustment of insulin to prevent lows, not a blanket reduction that might compromise overall glycemic control without guaranteeing awareness restoration. *Prescribe continuous glucose monitoring with predictive low glucose alerts* - **Continuous Glucose Monitoring (CGM)** with alerts is an excellent safety tool to prevent severe hypoglycaemic episodes by providing external warnings. - While CGM helps in preventing future lows, it acts as an external aid and does not physiologically
Question 55: A 6-year-old girl with epilepsy has been taking sodium valproate for 18 months with good seizure control. Her mother reports that she has recently noticed increased bruising and two episodes of epistaxis. Blood tests show: Haemoglobin 118 g/L, White cell count 6.8 × 10⁹/L, Platelets 185 × 10⁹/L, PT 13 seconds (normal range 11-14), APTT 38 seconds (normal range 26-34). What is the most likely explanation for these findings?
- A. Valproate-induced thrombocytopenia and platelet dysfunction
- B. Valproate-induced inhibition of von Willebrand factor synthesis (Correct Answer)
- C. Acquired haemophilia due to factor VIII inhibitor development
- D. Vitamin K deficiency secondary to enzyme induction
- E. Immune thrombocytopenic purpura as an autoimmune comorbidity
Explanation: ***Valproate-induced inhibition of von Willebrand factor synthesis*** - **Sodium valproate** can cause an acquired **von Willebrand syndrome** by reducing **von Willebrand factor (vWF)** levels and activity, which leads to impaired platelet adhesion. - This deficiency results in a prolonged **APTT** because **vWF** stabilizes **Factor VIII**, explaining the mucocutaneous bleeding (bruising, epistaxis) with a normal platelet count and PT. *Valproate-induced thrombocytopenia and platelet dysfunction* - While valproate can induce **thrombocytopenia**, the patient's **platelet count** of 185 × 10⁹/L is within the normal range, ruling out significant thrombocytopenia. - **Platelet dysfunction** would typically present with a normal **APTT**, whereas this patient has a significantly **prolonged APTT** of 38 seconds. *Acquired haemophilia due to factor VIII inhibitor development* - **Acquired haemophilia** is extremely rare in children and is not a recognized side effect of **sodium valproate** therapy. - This condition usually causes more severe, spontaneous **haematomas** or deep tissue bleeding, rather than just mucocutaneous symptoms. *Vitamin K deficiency secondary to enzyme induction* - **Sodium valproate** is an **enzyme inhibitor**, not an inducer, so it would not cause **vitamin K deficiency** through increased metabolism of clotting factors. - **Vitamin K deficiency** primarily prolongs the **Prothrombin Time (PT)**, which is normal (13 seconds) in this patient, while the APTT is prolonged. *Immune thrombocytopenic purpura as an autoimmune comorbidity* - **Immune thrombocytopenic purpura (ITP)** is characterized by a significantly low **platelet count**, usually below 100 × 10⁹/L, which contradicts this patient's normal platelet count. - In **ITP**, **coagulation times** (PT and APTT) are typically **normal**, which is inconsistent with the prolonged APTT seen here.
Question 56: A 13-year-old boy with type 1 diabetes for 7 years presents for his annual complication screening. Urinalysis shows albumin:creatinine ratio (ACR) of 3.5 mg/mmol on an early morning sample. Two further early morning samples over the next 3 months show ACR values of 3.8 mg/mmol and 4.1 mg/mmol. His blood pressure is 118/72 mmHg (95th percentile for age). HbA1c is 71 mmol/mol. eGFR is normal. What is the most appropriate initial management for his kidney disease?
- A. Commence ACE inhibitor therapy and intensify glycaemic control measures (Correct Answer)
- B. Intensify glycaemic control and arrange repeat screening in 12 months
- C. Refer to paediatric nephrology for kidney biopsy
- D. Commence angiotensin receptor blocker and strict low-protein diet
- E. Check for urinary tract infection and repeat testing when infection is excluded
Explanation: ***Commence ACE inhibitor therapy and intensify glycaemic control measures***- The patient has confirmed **persistent moderately increased albuminuria** (ACR 3.5-4.1 mg/mmol over 3 months), which is the earliest sign of **diabetic kidney disease** in Type 1 Diabetes.- **ACE inhibitors** are the first-line pharmacological intervention to provide **renoprotection** by reducing intraglomerular pressure, especially given his high-normal blood pressure (95th percentile), and intensifying **glycaemic control** (HbA1c 71 mmol/mol) is crucial to slow disease progression.*Intensify glycaemic control and arrange repeat screening in 12 months*- While **glycaemic control** is vital for preventing diabetic complications, simply arranging repeat screening in 12 months is insufficient for established **moderately increased albuminuria**.- Delaying the initiation of **renoprotective therapy** (like ACE inhibitors) increases the risk of progression to overt **macroalbuminuria** and further kidney damage.*Refer to paediatric nephrology for kidney biopsy*- A **kidney biopsy** is not indicated at this stage as the presentation with long-standing Type 1 Diabetes and persistent albuminuria is classic for **diabetic nephropathy**.- Biopsy is typically reserved for atypical features such as rapid decline in **eGFR**, presence of **haematuria**, or albuminuria without typical diabetic retinopathy.*Commence angiotensin receptor blocker and strict low-protein diet*- While **angiotensin receptor blockers (ARBs)** are an alternative to ACE inhibitors, they are usually reserved for patients intolerant to ACE inhibitors rather than initial therapy.- A **strict low-protein diet** is not recommended for children with early diabetic nephropathy as it can negatively impact their growth and development.*Check for urinary tract infection and repeat testing when infection is excluded*- The diagnosis of **persistent moderately increased albuminuria** has already been confirmed by three separate early morning samples over three months.- This consistent finding makes a transient cause like a **urinary tract infection (UTI)** highly unlikely, as UTIs cause temporary, not chronic, elevations in ACR.
Question 57: A 4-year-old boy presents to the emergency department with a focal seizure involving right-sided facial twitching that has been ongoing for 35 minutes. He remains conscious but unable to speak. There is no fever. He has no previous history of seizures. What is the most appropriate immediate management?
- A. Buccal midazolam 5 mg or intravenous lorazepam 0.1 mg/kg (Correct Answer)
- B. Intravenous phenytoin loading dose 20 mg/kg over 20 minutes
- C. Intravenous levetiracetam 40 mg/kg over 5 minutes
- D. Rectal diazepam 5 mg and observe
- E. Obtain urgent CT head before administering any anti-epileptic medication
Explanation: ***Buccal midazolam 5 mg or intravenous lorazepam 0.1 mg/kg*** - This patient is in **status epilepticus** (seizure lasting >5 minutes, or in this case, >30 minutes), which necessitates immediate first-line treatment with **benzodiazepines**. - **Buccal midazolam** (5 mg for ages 1–5 years) or **IV lorazepam** (0.1 mg/kg) are the recommended agents for rapid termination of status epilepticus in children due to their quick onset of action. *Intravenous phenytoin loading dose 20 mg/kg over 20 minutes* - **Phenytoin** is a **second-line** anti-epileptic drug for status epilepticus, used only if initial benzodiazepine treatment fails. - Its administration requires slower infusion rates and **cardiac monitoring**, making it unsuitable for the immediate, rapid termination required in the first few minutes of status epilepticus. *Intravenous levetiracetam 40 mg/kg over 5 minutes* - **Levetiracetam** is an alternative **second-line** agent for status epilepticus, similar to phenytoin or valproate, and is not indicated as the initial first-line treatment. - The immediate priority in status epilepticus is to administer a **benzodiazepine** to stop the seizure before considering non-benzodiazepine anticonvulsants. *Rectal diazepam 5 mg and observe* - While **rectal diazepam** can be used in emergency seizure management, **buccal midazolam** is generally preferred in most settings for its ease of administration and social acceptability. - Given the **35-minute duration** of the seizure, observation alone is inappropriate; active and aggressive treatment to terminate the seizure is critical to prevent neuronal damage. *Obtain urgent CT head before administering any anti-epileptic medication* - In a patient with **status epilepticus**, the absolute priority is **seizure termination** to prevent brain injury and systemic complications. - While **neuroimaging** is important for identifying the underlying cause, delaying life-saving anti-epileptic treatment to obtain a CT head is contraindicated.
Question 58: A 10-year-old girl with type 1 diabetes for 4 years presents with a 6-week history of intermittent abdominal pain, loose stools, and failure to gain weight. She has lost 2 kg. Her HbA1c has improved from 65 to 52 mmol/mol without changes to her insulin regimen. On examination, she appears pale and has angular stomatitis. What is the most likely diagnosis?
- A. Coeliac disease (Correct Answer)
- B. Improved glycaemic control with reduced caloric loss
- C. Diabetic gastroparesis
- D. Inflammatory bowel disease
- E. Exocrine pancreatic insufficiency
Explanation: ***Coeliac disease*** - Type 1 diabetes and **coeliac disease** share a strong genetic association (**HLA-DQ2/DQ8**), making this a common comorbidity, especially in children with diabetes. - The symptoms of **abdominal pain**, **loose stools**, **weight loss**, and **failure to thrive**, combined with **pallor** and **angular stomatitis** (due to nutrient deficiencies) and a **paradoxical improvement in HbA1c** (due to carbohydrate malabsorption), are highly indicative of coeliac disease. *Improved glycaemic control with reduced caloric loss* - While HbA1c has improved, this is not due to true improved glycaemic control, as evidenced by the concurrent **weight loss**, **abdominal pain**, and signs of **malnutrition**. - Genuine improved glycaemic control without insulin changes would stem from active dietary or lifestyle management, not from a pathological process causing nutrient malabsorption. *Diabetic gastroparesis* - **Diabetic gastroparesis** primarily causes symptoms like **nausea**, **vomiting**, **early satiety**, and **bloating** due to delayed gastric emptying, not typically loose stools or significant weight loss from malabsorption. - It is also a complication of **long-standing diabetes** and is less common in a child with only a 4-year history of the disease. *Inflammatory bowel disease* - While **inflammatory bowel disease** (IBD) can cause abdominal pain, weight loss, and loose stools, it does not typically lead to the specific **paradoxical decrease in HbA1c** through carbohydrate malabsorption. - Symptoms often include **bloody stools**, perianal disease, or distinct extra-intestinal manifestations, which are not described in this case. *Exocrine pancreatic insufficiency* - Although **exocrine pancreatic insufficiency** can cause malabsorption, **steatorrhea**, and weight loss, it is a far **less common** cause of these symptoms in Type 1 diabetes patients compared to coeliac disease. - It also wouldn't typically present with the specific constellation of symptoms, including the **paradoxical HbA1c improvement** and the particular micronutrient deficiencies suggested by angular stomatitis, as clearly as coeliac disease in this context.
Question 59: A 15-year-old girl with juvenile myoclonic epilepsy has been well-controlled on sodium valproate for 2 years. She now presents requesting advice about contraception as she is sexually active. Liver function tests and full blood count are normal. She has no plans for pregnancy. What is the most appropriate management regarding her anti-epileptic medication?
- A. Continue valproate but ensure effective contraception and comprehensive counselling about teratogenic risks with pregnancy prevention programme (Correct Answer)
- B. Switch immediately to levetiracetam as it has a better safety profile in women of childbearing potential
- C. Continue valproate without changes as she has no immediate pregnancy plans
- D. Switch to lamotrigine gradually, though risk of seizure recurrence is significant in juvenile myoclonic epilepsy
- E. Add folic acid 5mg daily and continue valproate unchanged
Explanation: ***Continue valproate but ensure effective contraception and comprehensive counselling about teratogenic risks with pregnancy prevention programme*** - **Sodium valproate** is the most effective treatment for **Juvenile Myoclonic Epilepsy (JME)**, and given she is well-controlled, continuing it is appropriate, provided robust measures are in place to prevent pregnancy. - The **Pregnancy Prevention Programme (PPP)** for valproate mandates **effective contraception** and comprehensive **counselling on teratogenic risks** (e.g., neural tube defects, developmental delay) for all females of childbearing potential, along with annual risk acknowledgement. *Switch immediately to levetiracetam as it has a better safety profile in women of childbearing potential* - While **levetiracetam** is safer in pregnancy, an immediate switch from a well-controlled regimen risks **seizure recurrence** or exacerbation, which could be dangerous. - **JME** is particularly responsive to valproate, and switching should be a carefully planned, gradual process, if at all, considering the patient's well-being and seizure control. *Continue valproate without changes as she has no immediate pregnancy plans* - This approach is unsafe and contrary to guidelines, as it exposes the patient to significant risks of **unplanned pregnancy** and severe **teratogenic effects** associated with valproate. - The absence of immediate pregnancy plans does not negate the need for active **risk management** and adherence to the **Pregnancy Prevention Programme (PPP)** for valproate. *Switch to lamotrigine gradually, though risk of seizure recurrence is significant in juvenile myoclonic epilepsy* - **Lamotrigine** can sometimes **exacerbate myoclonic seizures** in patients with **Juvenile Myoclonic Epilepsy (JME)**, making it a less suitable alternative for this specific syndrome. - While gradual switching is generally preferred for AEDs, selecting an agent known to worsen the patient's specific epilepsy type is inappropriate. *Add folic acid 5mg daily and continue valproate unchanged* - While **high-dose folic acid (5mg)** is crucial for women on valproate to reduce the risk of **neural tube defects**, it does not mitigate the broader **neurodevelopmental risks** (e.g., cognitive impairment) associated with valproate exposure. - Folic acid supplementation alone is insufficient and does not fulfill the comprehensive requirements of the **Pregnancy Prevention Programme (PPP)**, which includes robust contraception and counselling.
Question 60: A 12-year-old boy with type 1 diabetes for 5 years attends for routine screening. He is asymptomatic but fundoscopy reveals multiple microaneurysms and scattered dot-and-blot haemorrhages in both eyes, with no macular involvement or cotton wool spots. His HbA1c is 68 mmol/mol. What grade of diabetic retinopathy does this represent and what is the most appropriate management?
- A. Mild non-proliferative diabetic retinopathy; continue annual screening and optimize glycaemic control (Correct Answer)
- B. Moderate non-proliferative diabetic retinopathy; refer to ophthalmology for 6-monthly review
- C. Severe non-proliferative diabetic retinopathy; urgent ophthalmology referral for consideration of laser therapy
- D. Proliferative diabetic retinopathy; immediate ophthalmology referral for panretinal photocoagulation
- E. Diabetic maculopathy; urgent ophthalmology referral for consideration of intravitreal therapy
Explanation: ***Mild non-proliferative diabetic retinopathy; continue annual screening and optimize glycaemic control***- This stage is characterized by the presence of at least one **microaneurysm** and potentially scattered **dot-and-blot haemorrhages**, but lacks features of more advanced disease like **cotton wool spots** or macular involvement.- Management involves **optimizing glycaemic control** (reducing HbA1c to target) and blood pressure, with standard **annual digital retinal screening** if no maculopathy is present.*Moderate non-proliferative diabetic retinopathy; refer to ophthalmology for 6-monthly review*- **Moderate NPDR** typically shows more extensive haemorrhages (>20 in each quadrant) or the presence of **cotton wool spots** and venous beading in one quadrant.- This patient's description of "scattered" lesions without cotton wool spots fits the mild category, requiring standard annual review rather than a **6-monthly ophthalmic follow-up**.*Severe non-proliferative diabetic retinopathy; urgent ophthalmology referral for consideration of laser therapy*- **Severe NPDR** is diagnosed using the **4-2-1 rule**: extensive haemorrhages in 4 quadrants, venous beading in 2, or **IRMA** (intraretinal microvascular abnormalities) in 1, none of which are described here.- This stage carries a high risk of progression to proliferative disease and requires **urgent specialist referral**, but not based on these asymptomatic findings.*Proliferative diabetic retinopathy; immediate ophthalmology referral for panretinal photocoagulation*- **Proliferative retinopathy (PDR)** is defined by the presence of **neovascularization** (new vessel growth) at the disc or elsewhere, or vitreous haemorrhage, none of which are noted on fundoscopy.- Since no new vessels or significant ischaemic features were noted, **panretinal photocoagulation** is not indicated at this time.*Diabetic maculopathy; urgent ophthalmology referral for consideration of intravitreal therapy*- **Maculopathy** is specifically defined by the presence of lesions (exudates, haemorrhages, or oedema) within the **macular area**, which would impact central vision.- The scenario explicitly states there is **no macular involvement**, making this diagnosis and the need for **anti-VEGF intravitreal therapy** incorrect.
Practice by Chapter
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free